138 related articles for article (PubMed ID: 23880358)
21. Aminothiazolomorphinans with mixed κ and μ opioid activity.
Zhang T; Yan Z; Sromek A; Knapp BI; Scrimale T; Bidlack JM; Neumeyer JL
J Med Chem; 2011 Mar; 54(6):1903-13. PubMed ID: 21351746
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Decker M; Si YG; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2010 Jan; 53(1):402-18. PubMed ID: 19928862
[TBL] [Abstract][Full Text] [Related]
24. Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.
Truong PM; Hassan SA; Lee YS; Kopajtic TA; Katz JL; Chadderdon AM; Traynor JR; Deschamps JR; Jacobson AE; Rice KC
Bioorg Med Chem; 2017 Apr; 25(8):2406-2422. PubMed ID: 28314512
[TBL] [Abstract][Full Text] [Related]
25. Absolute configuration and conformation of the pure opioid antagonist (+)-2,9 alpha-dimethyl-5-(m-hydroxyphenyl)morphan.
Froimowitz M; Pangborn W; Cody V
Chirality; 1992; 4(6):377-83. PubMed ID: 1449951
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
27. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
[TBL] [Abstract][Full Text] [Related]
28. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
Provencher BA; Sromek AW; Li W; Russell S; Chartoff E; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2013 Nov; 56(21):8872-8. PubMed ID: 24107104
[TBL] [Abstract][Full Text] [Related]
30. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and opioid receptor activity of indolopropellanes.
Li F; Gaob L; Yin C; Chen J; Liu J; Xie X; Zhang A
Bioorg Med Chem Lett; 2009 Aug; 19(16):4603-6. PubMed ID: 19595591
[TBL] [Abstract][Full Text] [Related]
32. Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans.
Thomas JB; Atkinson RN; Namdev N; Rothman RB; Gigstad KM; Fix SE; Mascarella SW; Burgess JP; Vinson NA; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2002 Aug; 45(16):3524-30. PubMed ID: 12139463
[TBL] [Abstract][Full Text] [Related]
33. Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan.
Hashimoto A; Jacobson AE; Rothman RB; Dersch CM; George C; Flippen-Anderson JL; Rice KC
Bioorg Med Chem; 2002 Oct; 10(10):3319-29. PubMed ID: 12150879
[TBL] [Abstract][Full Text] [Related]
34. Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols.
Iyer MR; Lee YS; Deschamps JR; Rothman RB; Dersch CM; Jacobson AE; Rice KC
Bioorg Med Chem; 2010 Jan; 18(1):91-9. PubMed ID: 20005115
[TBL] [Abstract][Full Text] [Related]
35. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem; 2007 Jun; 15(12):4106-12. PubMed ID: 17433695
[TBL] [Abstract][Full Text] [Related]
36. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
[TBL] [Abstract][Full Text] [Related]
37. A critical structural determinant of opioid receptor interaction with phenolic 5-phenylmorphans.
Kim IJ; Dersch CM; Rothman RB; Jacobson AE; Rice KC
Bioorg Med Chem; 2004 Aug; 12(16):4543-50. PubMed ID: 15265502
[TBL] [Abstract][Full Text] [Related]
38. Chemistry of opium alkaloids. Part 44: synthesis and opioid receptor binding profile of substituted ethenoisomorphinans and ethenomorphinans.
Maat L; Woudenberg RH; Meuzelaar GJ; Linders JT
Bioorg Med Chem; 1999 Mar; 7(3):529-41. PubMed ID: 10220038
[TBL] [Abstract][Full Text] [Related]
39. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
